Biosonics Seeks FDA Approval for Alternative to Viagra.

FORT WASHINGTON, Penn.--(BW HealthWire)--June 30, 1998-- Biosonics, Inc. (OTC/BB: BISN) announced today that it is going forward with testing necessary in its efforts to obtain FDA marketing approval for MEGS(TM), a patented device which counteracts male impotence.

BISN holds a design patent for MEGS(TM) (Male Electronic Genital Stimulator) -- a non-invasive alternative to Pfizer's (NYSE:PFE) Viagra and Vivus(TM) (NASDAQ:VVUS) Muse(TM). Based on the market demand for Pfizer's Viagra(TM), BISN has decided to proceed with its efforts to make MEGS commercially available.

Jack Paller, Chief Executive Officer of BISN, explained the Company's decision, "MEGS(TM) is a non-invasive, non-pharmaceutical means of addressing male impotence. Given the public demand for a solution to male impotence, going forward with our efforts to make MEGS(TM) publicly available at this time makes sense."

BISN is involved in the development and marketing of electrotherapeutic and diagnostic devices to manageand treat several intractable medical conditions. To date, the Company holds six patents on its devices and has received FDA approval or clearance to market four of its products: Salitron(R) for dry mouth (competitor to MGI Pharmaceuticals' (NASDAQ:MOGN) product Saligen), Cystotron(TM) for urinary incontinence (competitor to EMPI Inc. (NASDAQ:EMPI) and Utah Medical), Anotron(TM) for fecal incontinence and the BIDDS(TM) glove which is a diagnostic tool. For additional information on BISN, please contact Raymond Bary of the NIBAR Group at 415/474-1647.

    CONTACT: NIBAR Group
              Raymond Bary, 415/474-1647